2013•European journal of clinical pharmacyRequires access
Filgrastim in solid organ transplant recipients
Virginia Bosó, Eduardo San Martín Ciges, Isabel Font Noguera, Carmen Planells Herrero, José Luís Poveda Andrés
Open publisher page 0 citations
Abstract
Leukopenia is common following solid organ transplantation. This study evaluates the use of filgrastim in solid organ transplant recipients by explicit pharmacotherapeutic criteria. Method: Descriptive and observational study. 26 solid organ transplant recipients were included. Facts related to justification of treatment, effectiveness and safety were assessed. Results: The most likely cause of leukopenia was drugs. Mycophenolate mofetil and valganciclovir were used simultaneously in 50% of the patients. The mean dose of filgrastim was 3.6 mcg/kg/day (95% CI = 2.8-4.4). The median length of therapy was seven days (range 4.5-15 days). The average duration of leukopenia was 5.5 days (95% CI = 4.2-6.7). 26.9% of the patients did not recover from leukopenia. Regression analysis showed no relationship between the duration of leukopenia and the dose of filgrastim. Conclusions: Filgrastim was able to regain the WBC counts in an appropriate period of time, allowing maintaining necessary drug treatments that otherwise would have been suspended